trending Market Intelligence /marketintelligence/en/news-insights/trending/1TeuG-GgDmk2iulB0lZlnw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Akorn names CEO

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


Akorn names CEO

Akorn Inc. appointed Douglas Boothe as the company's president and CEO, effective Jan. 1, 2019.

Boothe most recently served as president of Impax Laboratories Inc.'s generics division, since Aug. 1, 2016. In addition, he acted as executive vice president and general manager of prescription pharmaceuticals at Perrigo Co. PLC. He was also CEO, COO and executive vice president of Actavis LLC.

Lake Forest, Ill.-based Akorn is a specialty generic pharmaceutical company that develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter consumer health products, and animal health pharmaceuticals.